Park Ha Biological Technology is trading at $3.06 (-5.12%) after renewed coverage of securities class-action litigation alleging market manipulation, fraudulent promotion, and inadequate risk disclosures.

  • The lawsuit targets investors who purchased shares during December 27, 2024–July 8, 2025.
  • The lead-plaintiff deadline is September 28, 2026.
  • The decline follows August 6’s extraordinary 875.46% closing gain, suggesting heightened volatility and credibility concerns.